CD4 and systemic lupus erythematosus: However, in the CD4+ T cells derived from patients with SLE, the utilization of canagliflozin blunt TCR signaling, which in turn inhibits mTORC1 and Myc pathway, ultimately impeding CD4+ T cell function by metabolic suppression (impaired glutamine anaplerosis, glycolysis, and OXPHOS) (Table 1) (122).